New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
06:09 EDTTTHI, LLYTransition Therapeutics begins Phase 2 study of diabetes candidate TT-401
Transition Therapeutics (TTHI) dosed the first patient in a Phase 2 clinical study of TT-401, a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly (LLY). The objectives of the study will be to evaluate the safety and effectiveness of TT-401 compared to once-weekly exenatide extended release and placebo.
News For TTHI;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
09:20 EDTLLYARIAD drawing interest from companies besides Baxalta, dealReporter says
Subscribe for More Information
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use